Literature DB >> 3410347

Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing.

B U Sevin1, Z L Peng, J P Perras, P Ganjei, M Penalver, H E Averette.   

Abstract

Intracellular adenosine triphosphate (ATP) is the primary energy unit of living cells, and can be quantitated by measuring the light generated with luciferase-luciferin reagent in a luminometer. The use of an ATP-bioluminescence assay, to determine tumor cell viability after exposure to chemotherapeutic agents, has been adapted to test tumor chemosensitivity in vitro. This presentation will illustrate the method of the ATP-chemosensitivity assay (ATP-CSA) using an ovarian cancer cell line NIHL:OVCAR-3 as an example and present preliminary data on 54/56 successful in vitro ATP-CSA's from 46 patients with pelvic malignancies. Fresh human tumor specimens were generally tested for single and combined drug effects at two drug concentrations (0.2 X and 1 X peak plasma concentrations). Correlation of in vitro drug sensitivity and in vivo patient response was obtained for 23 treatment regimens in 22 patients with ovarian carcinoma. The true positive rate was 100% and the true negative rate 66.7%. Our data demonstrate (a) that the ATP-CSA, measuring total cell viability, is a feasible in vitro assay for human tumor drug testing and (b) that specific criteria of in vitro chemosensitivity for this assay need to be defined by further studies, for single and combined drug exposure at different concentrations, to permit a meaningful correlation with in vivo clinical response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410347     DOI: 10.1016/0090-8258(88)90293-4

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  33 in total

1.  Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Ramos; D Donato
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2011-05-21       Impact factor: 3.850

3.  ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

4.  Clinical outcomes of ATP-tumor chemosensitivity assay directed chemotherapy in hepatocellular carcinoma.

Authors:  Rongsheng Rao; Wenxue Chen; Xinwen Zhou; Zheng Zhou; Xiaojun Li; Zhiping Zeng
Journal:  Front Med China       Date:  2007-02-01

5.  Viability assays for cells in culture.

Authors:  Jessica M Posimo; Ajay S Unnithan; Amanda M Gleixner; Hailey J Choi; Yiran Jiang; Sree H Pulugulla; Rehana K Leak
Journal:  J Vis Exp       Date:  2014-01-20       Impact factor: 1.355

6.  In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Hightower; R Ramos; D Donato; M Penalver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.

Authors:  Bin Wei; Jiru Wang; Xiaohui Zhang; Zhaoye Qian; Jingjing Wu; Yuan Sun; Qin Han; Li Wan; Jing Zhu; Yong Gao; Xiaofei Chen
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

8.  Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer.

Authors:  Jee Hyun Kim; Keun-Wook Lee; Yeul Hong Kim; Kyung Hee Lee; Do Youn Oh; Joonhee Kim; Sung Hyun Yang; Seock-Ah Im; Sung Ho Choi; Yung-Jue Bang
Journal:  J Korean Med Sci       Date:  2010-04-21       Impact factor: 2.153

9.  Long-term survival in stage III and IV ovarian cancer.

Authors:  E Petru; B U Sevin; H E Averette; O R Koechli; S Hilsenbeck
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

10.  Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.

Authors:  Jung Wook Huh; Yoon Ah Park; Kang Young Lee; Seung-Kook Sohn
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.